A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

被引：6
|
作者：
Murthy, Guru Subramanian Guru [1 ]
Leonard, Jessica T. [2 ]
Badar, Talha [3 ]
Yi, Cecilia Y. Arana [4 ]
Duvall, Adam S. [5 ]
Shah, Bijal D. [6 ]
Baim, Arielle [7 ]
Kearl, Tyce [8 ]
Harrington, Alexandra M. [7 ]
Szabo, Aniko [7 ]
Atallah, Ehab L. [8 ]
机构：
[1] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA
[2] Oregon Hlth & Sci Univ, Dept Hematol & Med Oncol, Portland, OR 97201 USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
[4] Mayo Clin, Hematol Oncol, Scottsdale, AZ USA
[5] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA
[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[8] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187721
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Murthy, Guru Subramanian Guru
    Kearl, Tyce
    Cui, Weigo
    Johnson, Bryon
    Hoffmeister, Karin
    Harrington, Alexandra
    Szabo, Aniko
    Badar, Talha
    Duvall, Adam
    Leonard, Jessica Taft
    Yi, Cecilia Ysabel Arana
    Baim, Arielle
    Yaghoubi, Shahriar
    Shah, Bijal D.
    Stock, Wendy
    Atallah, Ehab L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
    Murthy, Guru Subramanian Guru
    Shah, Bijal D.
    Duvall, Adam S.
    Leonard, Jessica T.
    Badar, Talha
    Yi, Cecilia Y. Arana
    Kearl, Tyce
    Baim, Arielle
    Harrington, Alexandra M.
    Szabo, Aniko
    Atallah, Ehab L.
    BLOOD, 2023, 142
  • [3] A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma
    Murthy, Guru Subramanian Guru
    Kearl, Tyce J.
    Cui, Weiguo
    Johnson, Bryon
    Hoffmeister, Karin
    Szabo, Aniko
    Aoki, Kazuhiro
    Harrington, Alexandra M.
    Carlson, Karen
    Michaelis, Laura C.
    Runaas, Lyndsey
    Abedin, Sameem
    Duvall, Adam S.
    Stock, Wendy
    Shah, Bijal D.
    Leonard, Jessica
    Pratz, Keith W.
    Luger, Selina M.
    Badar, Talha
    Baim, Arielle
    Yaghoubi, Shahriar
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [4] CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics
    Barbora, Vakrmanova
    Michaela, Novakova
    Petr, Riha
    Marketa, Zaliova
    Eva, Fronkova
    Ester, Mejstrikova
    Jan, Stary
    Ondrej, Hrusak
    Lucie, Sramkova
    PEDIATRIC BLOOD & CANCER, 2022, 69 (09)
  • [5] Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression
    Zhang, Yanni
    Sheng, Zhen
    Xia, Jie
    Ye, Chunyan
    Liu, Yan
    Wang, Zhengyi
    Hayslip, John
    Zhu, Andrew
    BLOOD, 2022, 140 : 9937 - 9938
  • [6] CD38 Glycosylation Determines Antibody Recognition in Myeloid Leukemia Cell Lines
    Steenackers, Agata
    Rosenbalm, Katelyn E.
    Weich, Natalia
    Hoffmeister, Karin M.
    GLYCOBIOLOGY, 2023, 33 (11) : 1045 - 1045
  • [7] Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
    Meike Farber
    Yiyang Chen
    Lucas Arnold
    Michael Möllmann
    Eva Boog-Whiteside
    Yu-An Lin
    H. Christian Reinhardt
    Ulrich Dührsen
    Maher Hanoun
    Scientific Reports, 11
  • [8] Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia
    Martin-Sanchez, Esperanza
    Blanco, Laura
    Kim, Peter S.
    Bisht, Kamlesh
    Wang, Hongfang
    van de Velde, Helgi
    Jelinek, Tomas
    Simoes, Catia
    Prosper, Felipe
    Miguel, Jesus F. San
    Alfonso, Ana
    Bergua, Juan
    Rodriguez-Veiga, Rebeca
    Vives, Susana
    Martinez-Cuadron, David
    Montesinos, Pau
    Paiva, Bruno
    Zabaleta, Aintzane
    BLOOD ADVANCES, 2024, 8 (15) : 3875 - 3879
  • [9] Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
    Farber, Meike
    Chen, Yiyang
    Arnold, Lucas
    Moellmann, Michael
    Boog-Whiteside, Eva
    Lin, Yu-An
    Reinhardt, H. Christian
    Duehrsen, Ulrich
    Hanoun, Maher
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [10] Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
    Kazandjian, Dickran
    Quach, Hang
    Sia, Hanlon
    Ho, Phoebe Joy
    Spencer, Andrew
    Schroeder, Mark A.
    Dhakal, Binod
    Cochrane, Tara
    Zonder, Jeffrey A.
    Yi, Nancy
    Duchesne, Dominique
    Shah, Tejas
    Garton, Andrew
    Menon, Vinu
    Gn, Sunitha
    Sammicheli, Stefano
    Zhukovsky, Eugene
    Konto, Cyril
    Pacaud, Lida
    Tan, Peter
    BLOOD, 2023, 142
12345